197 related articles for article (PubMed ID: 28360139)
1. A Pyrrole-Imidazole Polyamide Is Active against Enzalutamide-Resistant Prostate Cancer.
Kurmis AA; Yang F; Welch TR; Nickols NG; Dervan PB
Cancer Res; 2017 May; 77(9):2207-2212. PubMed ID: 28360139
[TBL] [Abstract][Full Text] [Related]
2. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
3. Sequence specific suppression of androgen receptor-DNA binding in vivo by a Py-Im polyamide.
Kurmis AA; Dervan PB
Nucleic Acids Res; 2019 May; 47(8):3828-3835. PubMed ID: 30838415
[TBL] [Abstract][Full Text] [Related]
4. Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease.
Smith R; Liu M; Liby T; Bayani N; Bucher E; Chiotti K; Derrick D; Chauchereau A; Heiser L; Alumkal J; Feiler H; Carroll P; Korkola JE
Sci Rep; 2020 Dec; 10(1):21750. PubMed ID: 33303959
[TBL] [Abstract][Full Text] [Related]
5. Tumor Repression of VCaP Xenografts by a Pyrrole-Imidazole Polyamide.
Hargrove AE; Martinez TF; Hare AA; Kurmis AA; Phillips JW; Sud S; Pienta KJ; Dervan PB
PLoS One; 2015; 10(11):e0143161. PubMed ID: 26571387
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
Isikbay M; Otto K; Kregel S; Kach J; Cai Y; Vander Griend DJ; Conzen SD; Szmulewitz RZ
Horm Cancer; 2014 Apr; 5(2):72-89. PubMed ID: 24615402
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
8. The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy.
Puhr M; Hoefer J; Eigentler A; Ploner C; Handle F; Schaefer G; Kroon J; Leo A; Heidegger I; Eder I; Culig Z; Van der Pluijm G; Klocker H
Clin Cancer Res; 2018 Feb; 24(4):927-938. PubMed ID: 29158269
[No Abstract] [Full Text] [Related]
9. TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.
Palit SA; Vis D; Stelloo S; Lieftink C; Prekovic S; Bekers E; Hofland I; Šuštić T; Wolters L; Beijersbergen R; Bergman AM; Győrffy B; Wessels LF; Zwart W; van der Heijden MS
Elife; 2019 Dec; 8():. PubMed ID: 31855178
[TBL] [Abstract][Full Text] [Related]
10. Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor.
Adelaiye-Ogala R; Gryder BE; Nguyen YTM; Alilin AN; Grayson AR; Bajwa W; Jansson KH; Beshiri ML; Agarwal S; Rodriguez-Nieves JA; Capaldo B; Kelly K; VanderWeele DJ
Mol Cancer Ther; 2020 Jul; 19(7):1436-1447. PubMed ID: 32371590
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.
Zhang Z; Cheng L; Li J; Farah E; Atallah NM; Pascuzzi PE; Gupta S; Liu X
Cancer Res; 2018 Jun; 78(12):3147-3162. PubMed ID: 29700003
[TBL] [Abstract][Full Text] [Related]
12. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
[TBL] [Abstract][Full Text] [Related]
13. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S
Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603
[TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Kregel S; Chen JL; Tom W; Krishnan V; Kach J; Brechka H; Fessenden TB; Isikbay M; Paner GP; Szmulewitz RZ; Vander Griend DJ
Oncotarget; 2016 May; 7(18):26259-74. PubMed ID: 27036029
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide.
Xia X; Huang C; Liao Y; Liu Y; He J; Guo Z; Jiang L; Wang X; Liu J; Huang H
J Exp Clin Cancer Res; 2019 May; 38(1):220. PubMed ID: 31126320
[TBL] [Abstract][Full Text] [Related]
17. NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells.
Farah E; Li C; Cheng L; Kong Y; Lanman NA; Pascuzzi P; Lorenz GR; Zhang Y; Ahmad N; Li L; Ratliff T; Liu X
J Biol Chem; 2019 May; 294(21):8543-8554. PubMed ID: 30940724
[TBL] [Abstract][Full Text] [Related]
18. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
Zhu Y; Liu C; Armstrong C; Lou W; Sandher A; Gao AC
Clin Cancer Res; 2015 Sep; 21(18):4133-42. PubMed ID: 25995342
[TBL] [Abstract][Full Text] [Related]
19. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
[TBL] [Abstract][Full Text] [Related]
20. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]